From September 6 to 7 2024, the Porton Wecare Program accompanied the families of four Chongqing DMD patients to Shanghai to participate in the 13th China Rare Disease Summit 2024.
The summit, co-sponsored by the Chinese Organization for Rare Disorders …
As a proud gold sponsor of the Pharma Crystallization Summit 2024 (PCS 2024), the Crystallization Team at Porton, with locations in New Jersey (USA) and Shanghai (China), offers expert services in polymorph discovery and selection, crystallization process development, particle …
CPhI Europe (October 8-10) in Milan, Italy, stands as a worldwide event in the pharmaceutical industry, bringing together key players, thought leaders, and businesses from across the globe. At this year’s exhibition, Porton will showcase its end-to-end global CDMO service …
In the pharmaceutical industry, the development of crystallization processes—including for APIs and intermediates, as well as early-stage formulation development—plays a crucial role in the drug development and manufacturing process. Different crystal forms, sizes, and habits can significantly influence the physicochemical …
On July 16, 2024, Porton Pharma Solutions Ltd. (hereinafter referred to as “Porton”, “the company”, “We”) announced that its Chongqing Changshou Site (CQ2) had undergone a cGMP (current Good Manufacturing Practice) on-site inspection by the U.S. Food and Drug Administration …
Recently, the crystallization team at Porton and Genentech, Inc. jointly published a paper titled “Phase Transitions Involving Channel Hydrates of a New Pharmaceutical Compound” in 《Pharmaceutical Research》, the official journal of the American Association of Pharmaceutical Scientists. This journal focuses …
On June 14, 2024, Dr. Francesco Fontana (R&D Director), Dr. Dario Telese (Lead Chemist), and Dr. Lucija Ptiček (Synthesis Laboratory Specialist) from the Porton Slovenian site presented a lecture on the Master PRO-API program of the University of Perugia. The …
June 2024 — Porton J-STAR today announced that Enabling Technologies Consortium (ETC) has awarded a two-year contract to J-STAR to collaborate on “Co-processing Platform Technology.”
The primary goal of co-processing is to improve the reliability and efficiency of drug product …
As the global market for biopharmaceutical research outsourcing continues to flourish, the annual BOS Basel Conference has once again drawn worldwide attention. Since its inception in 2006, the Biotech Outsourcing Strategies (BOS) Events has become a barometer for the research …
We’ve had an exciting few days at CPhI North America. We want to express our sincere gratitude to all the present and potential future partners we’ve engaged with. Whether you require assistance with API route scouting, chemistry optimization, or the …
